NASDAQ:PHAS PhaseBio Pharmaceuticals (PHAS) Stock Forecast, Price & News $0.0006 0.00 (0.00%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$0.0006▼$0.000650-Day Range N/A52-Week Range$0.07▼$4.08Volume5,810 shsAverage Volume848,888 shsMarket Capitalization$29,914.80P/E RatioN/ADividend YieldN/APrice Target$4.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability PhaseBio Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside749,900.0% Upside$4.50 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.69 out of 5 stars 3.0 Analyst's Opinion Consensus RatingPhaseBio Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.50, PhaseBio Pharmaceuticals has a forecasted upside of 749,900.0% from its current price of $0.00.Amount of Analyst CoveragePhaseBio Pharmaceuticals has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PHAS. Previous Next 0.0 Dividend Strength Dividend YieldPhaseBio Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhaseBio Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePhaseBio Pharmaceuticals has received a 77.11% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services of the circulatory system" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for PhaseBio Pharmaceuticals is -0.55. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows2 people have added PhaseBio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PhaseBio Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.90% of the stock of PhaseBio Pharmaceuticals is held by insiders.Percentage Held by Institutions49.02% of the stock of PhaseBio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of PhaseBio Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PhaseBio Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About PhaseBio Pharmaceuticals (NASDAQ:PHAS) StockPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.Read More Receive PHAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAS Stock News HeadlinesMay 12, 2023 | marketwatch.com8-K: PhaseBio Pharmaceuticals IncMarch 31, 2023 | finanznachrichten.deAbsci Corporation: Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating ResultsJune 2, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. March 31, 2023 | finanznachrichten.deBioCryst Pharmaceuticals, Inc.: BioCryst Appoints Dr. Nancy Hutson as Chair of the BoardMarch 31, 2023 | finance.yahoo.comBioCryst Appoints Dr. Nancy Hutson as Chair of the BoardMarch 22, 2023 | marketwatch.comCardiomyopathy Medication Market Size and Forecast till 2031February 28, 2023 | marketwatch.comCardiomyopathy Medication Market Emerging Demand and Drive Growth by 2028 with Top Countries DataJanuary 17, 2023 | benzinga.comSFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio PharmaceuticalsJune 2, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. January 5, 2023 | bizjournals.comBankruptcy court approves PhaseBio's $32.9M asset transfer dealNovember 8, 2022 | marketwatch.comBankrupt PhaseBio Identifies Chiesi as Lead Bidder for Bentracimab AssetsNovember 4, 2022 | benzinga.comShort Volatility Alert: PhaseBio Pharmaceuticals, Inc.November 2, 2022 | msn.comWhy Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day SessionNovember 1, 2022 | msn.comWhy Goodyear Tire & Rubber Shares Are Trading Lower; Here Are 24 Stocks Moving PremarketOctober 27, 2022 | benzinga.comPhaseBio Pharmaceuticals 10% Owner Trades Company's StockOctober 25, 2022 | wsj.comPhaseBio Files for Bankruptcy Following Blackstone-Backed Partner’s LawsuitOctober 25, 2022 | bizjournals.comPhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $100MOctober 24, 2022 | nasdaq.comPhaseBio Pharma Files For Chapter 11 Bankruptcy ProtectionOctober 24, 2022 | finance.yahoo.comPhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy CodeOctober 24, 2022 | finance.yahoo.comPhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $60MOctober 24, 2022 | finance.yahoo.comPhaseBio Files for Bankruptcy With Plans to Sell AssetsOctober 19, 2022 | bizjournals.comCash-strapped PhaseBio sued by drug development partner in dispute over experimental therapyOctober 6, 2022 | finance.yahoo.comPhaseBio Might Have To Return Global Rights To Its Lead ProgramOctober 3, 2022 | finance.yahoo.comHypertension Clinical Trials Pipeline Analysis: 90+ Companies are Working to Improve the Treatment Space | DelveInsightSeptember 29, 2022 | finance.yahoo.comWhy an East Bay company wants control of its partner's blood thinner antidoteSeptember 28, 2022 | seekingalpha.comPhaseBio sinks ~67% after getting transfer notice for lead drug bentracimab's businessAugust 14, 2022 | seekingalpha.comPhaseBio Pharmaceuticals (PHAS) Investor Presentation - SlideshowSee More Headlines PHAS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHAS Company Calendar Last Earnings11/10/2021Today6/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PHAS CUSIPN/A CIK1169245 Webwww.phasebio.com Phone(610) 981-6500FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.50 High Stock Price Forecast$8.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+749,900.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-131,070,000.00 Net Margins-12,572.13% Pretax Margin-12,572.13% Return on EquityN/A Return on Assets-174.38% Debt Debt-to-Equity RatioN/A Current Ratio0.47 Quick Ratio0.47 Sales & Book Value Annual Sales$818,000.00 Price / Sales0.04 Cash FlowN/A Price / Cash FlowN/A Book Value($1.93) per share Price / Book0.00Miscellaneous Outstanding Shares49,858,000Free Float44,922,000Market Cap$29,914.80 OptionableNot Optionable Beta2.57 Key ExecutivesJonathan P. MowChief Executive Officer & DirectorJohn P. SharpChief Financial OfficerJohn S. LeeChief Medical OfficerKristopher L. HansonSecretary, Senior VP & General CounselSusan E. ArnoldSenior Vice President-Technical OperationsKey CompetitorsAllied Healthcare ProductsNASDAQ:AHPIAllena PharmaceuticalsNASDAQ:ALNAQLAVA TherapeuticsNASDAQ:LVTXNLS PharmaceuticsNASDAQ:NLSPPharvarisNASDAQ:PHVSView All CompetitorsInsidersEnterprise Associates 13 L NewSold 1,784,109 sharesTotal: $267,616.35 ($0.15/share)View All Insider Transactions PHAS Stock - Frequently Asked Questions Should I buy or sell PhaseBio Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PHAS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PHAS, but not buy additional shares or sell existing shares. View PHAS analyst ratings or view top-rated stocks. What is PhaseBio Pharmaceuticals' stock price forecast for 2023? 5 analysts have issued 1-year price objectives for PhaseBio Pharmaceuticals' shares. Their PHAS share price forecasts range from $1.00 to $8.00. On average, they anticipate the company's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 749,900.0% from the stock's current price. View analysts price targets for PHAS or view top-rated stocks among Wall Street analysts. How have PHAS shares performed in 2023? PhaseBio Pharmaceuticals' stock was trading at $0.0301 at the start of the year. Since then, PHAS shares have decreased by 98.0% and is now trading at $0.0006. View the best growth stocks for 2023 here. How were PhaseBio Pharmaceuticals' earnings last quarter? PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by $0.07. The company had revenue of $0.34 million for the quarter, compared to analyst estimates of $2.67 million. What other stocks do shareholders of PhaseBio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX). When did PhaseBio Pharmaceuticals IPO? (PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager. What is PhaseBio Pharmaceuticals' stock symbol? PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS." How do I buy shares of PhaseBio Pharmaceuticals? Shares of PHAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is PhaseBio Pharmaceuticals' stock price today? One share of PHAS stock can currently be purchased for approximately $0.00. How much money does PhaseBio Pharmaceuticals make? PhaseBio Pharmaceuticals (NASDAQ:PHAS) has a market capitalization of $29,914.80 and generates $818,000.00 in revenue each year. The company earns $-131,070,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. How can I contact PhaseBio Pharmaceuticals? PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The official website for the company is www.phasebio.com. The company can be reached via phone at (610) 981-6500 or via email at pmobley@nobleromans.com. This page (NASDAQ:PHAS) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PhaseBio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.